Takeda Competitors

Pink Sheets . USA . 
Stock . Takeda Pharmaceutical Co
TKPHF Stock  USD 31.12  0.70  2.30%   
Takeda Pharmaceutical competes with Haleon Plc, Ipsen SA, Daiichi Sankyo, WuXi AppTec, and Daiichi Sankyo; as well as few others. The company classifies itself under Healthcare sector and is part of Drug Manufacturers—Specialty & Generic industry. Analyzing Takeda Pharmaceutical competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Takeda Pharmaceutical to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Takeda Pharmaceutical Correlation with its peers.

Takeda Pharmaceutical vs Lonza Group Correlation

Very weak diversification

The correlation between Takeda Pharmaceutical Co and LZAGY is 0.49 (i.e., Very weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Takeda Pharmaceutical Co and LZAGY in the same portfolio, assuming nothing else is changed.

Moving together with Takeda Pink Sheet

  0.92MKKGY Merck KGaA ADRPairCorr
  0.89MKGAF MERCK KommanditgesellsPairCorr
  0.91TAK Takeda PharmaceuticalPairCorr
  0.68HLN Haleon plcPairCorr

Moving against Takeda Pink Sheet

  0.59PTAIF PT Astra InternationalPairCorr
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
29.6831.1232.56
Details
Intrinsic
Valuation
LowRealHigh
28.0135.4836.92
Details
Naive
Forecast
LowNextHigh
29.2730.7132.15
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
30.4931.2231.95
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Takeda Pharmaceutical. Your research has to be compared to or analyzed against Takeda Pharmaceutical's peers to derive any actionable benefits. When done correctly, Takeda Pharmaceutical's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Takeda Pharmaceutical.

Takeda Pharmaceutical Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Takeda Pharmaceutical and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of Takeda and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Takeda Pharmaceutical does not affect the price movement of the other competitor.

High positive correlations

DSNKY
+ 0.92
DSKYF
SDZNY
+ 0.77
HLNCF
LZAGY
+ 0.68
WUXAY
WUXAY
+ 0.63
WUXIF
SDZNY
+ 0.58
IPSEY
WUXAY
+ 0.58
IPSEY
  

High negative correlations

SDZNY
- 0.76
DSNKY
SDZNY
- 0.74
DSKYF
DSKYF
- 0.63
HLNCF
DSKYF
- 0.61
IPSEY
DSNKY
- 0.6
HLNCF
DSNKY
- 0.55
IPSEY

Risk-Adjusted Indicators

There is a big difference between Takeda Pink Sheet performing well and Takeda Pharmaceutical Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Takeda Pharmaceutical's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
HLNCF  1.56  0.17  0.06  1.13  1.93 
(1.79)
 4.25 
(4.20)
 9.42 
CHALF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
IPSEY  1.08  0.23  0.10  7.21  1.00 
(2.21)
 4.09 
(2.11)
 10.60 
DSKYF  3.01 (0.43) 0.00 (0.64) 0.00 
 0.00 
 6.37 
(6.88)
 17.89 
WUXIF  0.46 (0.09) 0.00 (1.09) 0.00 
 0.00 
 0.00 
 0.00 
 13.69 
DSNKY  1.97 (0.56) 0.00 (0.51) 0.00 
 0.00 
 3.96 
(4.12)
 10.19 
SDZNY  1.33  0.34  0.20  0.73  1.23 
(1.48)
 3.14 
(1.97)
 9.00 
WUXAY  1.61 (0.09) 0.00 (0.20) 0.00 
 0.00 
 4.00 
(4.15)
 9.24 
HOCPF  1.29  0.07  0.00 (0.17) 2.05 
(4.79)
 5.00 
(5.27)
 16.45 
LZAGY  1.08 (0.14) 0.00 (0.15) 0.00 
 0.00 
 2.19 
(1.98)
 7.08 

Takeda Pharmaceutical Competitive Analysis

The better you understand Takeda Pharmaceutical competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Takeda Pharmaceutical's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Takeda Pharmaceutical's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
TKPHF HLNCF CHALF IPSEY DSKYF WUXIF DSNKY SDZNY WUXAY HOCPF
 2.30 
 31.12 
Takeda
 0.58 
 5.22 
Haleon
 0.00 
 0.0001 
Chalice
 1.09 
 40.76 
Ipsen
 3.32 
 18.91 
Daiichi
 4.21 
 13.88 
WuXi
 6.09 
 18.20 
Daiichi
 1.97 
 79.28 
Sandoz
 1.87 
 14.14 
WuXi
 3.01 
 158.77 
HOYA
Market Volatility
(90 Days Market Risk)
Very steady
Somewhat reliable
Very steady
Very steady
Not too volatile
Not too volatile
Not too volatile
Unknown risk
Not too volatile
Very steady
Market Performance
(90 Days Performance)
Good
Mild
Weakest
Good
Weakest
Weakest
Weakest
Good
Soft
Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Low
High
Low
Low
Low
Low
Unknown
Low
Low
Current Valuation
(Equity Enterprise Value)
Under Valued
Fairly Valued
Over Valued
Fairly Valued
Over Valued
Fairly Valued
Over Valued
Under Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Buy
Sell
Strong Sell
Strong Hold
Strong Sell
Cautious Hold
Cautious Hold
Strong Buy
Strong Sell
Strong Sell
Current Ratio
1.18
3.43
0.61
1.88
3.36
1.46
3.36
N/A
1.46
4.43
Net Asset
13.18 T
34.45 B
28.02 M
5.61 B
2.22 T
55.13 B
2.22 T
N/A
55.13 B
992.84 B
Profit Margin
0.0696
0.13
-0.22
0.21
0.0502
0.26
0.0502
N/A
0.26
0.23
EBITDA
1.05 T
1.92 B
(4.77 M)
1.06 B
137.51 B
7.43 B
137.51 B
N/A
7.43 B
255.39 B
Operating Margin
0.13
0.2
-0.1
0.28
0.0646
0.21
0.0646
N/A
0.21
0.29
Current Valuation
75.53 B
46.45 B
13.75 M
8.28 B
57.82 B
32.25 B
57.82 B
N/A
32.87 B
33.23 B
Price To Book
0.97
1.05
0.16
2.73
5.85
4.94
5.98
N/A
4.63
6.2
Retained Earnings
1.57 T
N/A
N/A
N/A
1.03 T
N/A
1.03 T
N/A
N/A
505.27 B
Current Asset
1.48 T
N/A
N/A
N/A
1.19 T
N/A
1.19 T
N/A
N/A
427.5 B
Five Year Return
3.99
N/A
N/A
1.1
2.01
N/A
1.21
N/A
N/A
0.84
Beta
0.7
N/A
0.53
0.7
0.47
0.74
0.47
N/A
0.74
0.68
Number Of Employees
47.35 K
22 K
5
5 K
16.46 K
45.65 K
16.46 K
N/A
45.65 K
38.38 K
Shares Outstanding
1.56 B
9.23 B
65.33 M
330.56 M
1.92 B
395.32 M
1.92 B
N/A
2.96 B
356.4 M
Cash Flow From Operations
1.12 T
1.36 B
(1.46 M)
971.4 M
139.23 B
4.59 B
139.23 B
N/A
4.59 B
190.06 B
Annual Yield
0.0428
N/A
N/A
0.0114
0.0072
0.0064
0.0065
N/A
0.0067
0.0076
Total Debt
4.14 T
10.31 B
6.8 M
562.8 M
143.07 B
607.14 M
143.07 B
N/A
607.14 M
13.76 B
Return On Equity
0.0477
N/A
-0.58
0.19
0.0432
0.22
0.0432
N/A
0.22
0.21
Z Score
N/A
1.8
0.6
9.6
N/A
37.8
N/A
N/A
38.4
1.2
Return On Asset
0.0247
N/A
-0.046
0.1
0.0209
0.0786
0.0209
N/A
0.0786
0.13
Book Value Per Share
3972.91
2.91
0.28
10.13
737.72
15.14
737.72
N/A
15.14
2256.63
Current Liabilities
808.72 B
N/A
N/A
N/A
381.29 B
N/A
381.29 B
N/A
N/A
122.39 B
Total Asset
13.18 T
34.45 B
28.02 M
5.61 B
2.22 T
55.13 B
2.22 T
N/A
55.13 B
992.84 B
Debt To Equity
0.81
0.38
0.69
0.38
0.12
0.12
0.12
N/A
0.12
0.028
Last Dividend Paid
180.0
N/A
N/A
1.2
13.5
0.52
13.5
N/A
0.52
155.0
Target Price
N/A
N/A
N/A
N/A
40.93
N/A
N/A
N/A
N/A
N/A
Shares Owned By Institutions
41.35
26.57
N/A
N/A
56.22
62.8
0.21
N/A
N/A
55.53
Market Capitalization
50.37 B
36.52 B
11.4 M
9.26 B
59.84 B
38.36 B
60.9 B
N/A
39.14 B
38.67 B
Price To Earning
27.54
17.5
N/A
14.23
91.96
48.46
92.74
N/A
23.08
34.67
Price To Earnings To Growth
0.58
N/A
N/A
N/A
31575.3
N/A
N/A
N/A
N/A
N/A
Price To Sales
0.0127
3.41
0.48
2.72
0.0568
0.95
0.0568
N/A
0.95
0.0508
Net Income
230.06 B
1.39 B
(10.03 M)
648.6 M
66.97 B
5.1 B
66.97 B
N/A
5.1 B
164.51 B
Earnings Per Share
1.33
0.17
-0.11
1.92
0.24
0.42
0.24
N/A
0.4
3.48
Shares Owned By Insiders
1.2
38.54
21.3
N/A
1.45
0.05
N/A
N/A
N/A
1.2
Revenue
3.57 T
9.54 B
21.91 M
3.16 B
1.04 T
22.9 B
1.04 T
N/A
22.9 B
670.33 B
Working Capital
675.58 B
N/A
N/A
N/A
806.14 B
N/A
806.14 B
N/A
N/A
305.12 B
Cash And Equivalents
645.99 B
1.33 B
741.17 K
1.07 B
807.19 B
9.28 B
807.19 B
N/A
9.28 B
434.47 B
Cash Per Share
417.82
0.14
0.01
3.24
421.1
3.14
421.1
N/A
3.14
N/A
Gross Profit
2.44 T
5.99 B
6.76 M
2.63 B
691.56 B
8.28 B
691.56 B
N/A
8.28 B
367.8 B
Day Typical Price
31.12
5.2
1.0E-4
40.76
18.76
13.88
18.3
79.46
14.2
158.77
Accumulation Distribution
N/A
0.0581
N/A
N/A
0.0243
N/A
0.0577
0.0114
0.0119
N/A
Market Facilitation Index
N/A
0.31
N/A
N/A
0.46
N/A
1.09
0.91
0.17
N/A
Daily Balance Of Power
9.2 T
0.0968
0.0
0
(1.41)
0
(1.08)
(1.75)
(1.59)
9.2 T
Period Momentum Indicator
0.7
0.03
N/A
(0.45)
(0.65)
(0.61)
(1.18)
(1.59)
(0.27)
4.64
Rate Of Daily Change
1.02
1.01
1.0
0.99
0.97
0.96
0.94
0.98
0.98
1.03
Day Median Price
31.12
5.19
1.0E-4
40.76
18.68
13.88
18.35
79.56
14.23
158.77
Price Action Indicator
0.35
0.05
N/A
(0.23)
(0.1)
(0.30)
(0.74)
(1.07)
(0.22)
2.32
Relative Strength Index
67.04
60.89
N/A
69.26
41.68
38.5
35.76
58.72
52.83
55.21
Coefficient Of Variation
1388.86
1174.96
N/A
767.98
(983.38)
(2,197)
(506.75)
461.74
(3,444)
4145.32
Mean Deviation
0.7486
1.56
N/A
1.08
3.01
0.4634
1.97
1.33
1.61
1.29
Jensen Alpha
0.0981
0.1662
N/A
0.2252
(0.43)
(0.09)
(0.56)
0.3386
(0.09)
0.0664
Total Risk Alpha
0.0286
0.0685
N/A
0.1386
(0.60)
(0.17)
(0.65)
0.274
(0.18)
(0.08)
Sortino Ratio
0.0278
0.0601
N/A
0.0981
N/A
N/A
N/A
0.201
N/A
0.0032
Downside Variance
6.78
5.16
N/A
3.81
N/A
N/A
N/A
2.54
N/A
39.94
Standard Deviation
1.63
2.13
N/A
1.81
3.91
1.74
2.62
1.69
2.23
2.7
Kurtosis
6.65
0.3285
N/A
4.61
0.2617
25.66
0.6458
0.4019
0.1676
3.49
Potential Upside
2.47
4.25
N/A
4.09
6.37
N/A
3.96
3.14
4.0
5.0
Treynor Ratio
0.4077
1.13
N/A
7.21
(0.64)
(1.09)
(0.51)
0.7344
(0.20)
(0.17)
Maximum Drawdown
9.98
9.42
N/A
10.6
17.89
13.69
10.19
9.0
9.24
16.45
Variance
2.65
4.55
N/A
3.29
15.31
3.04
6.85
2.85
4.99
7.31
Market Risk Adjusted Performance
0.4177
1.14
N/A
7.22
(0.63)
(1.08)
(0.50)
0.7444
(0.19)
(0.16)
Risk Adjusted Performance
0.0576
0.0682
N/A
0.1002
(0.07)
(0.03)
(0.14)
0.1623
(0.01)
0.0248
Skewness
0.9558
(0.01)
N/A
1.06
0.0547
1.58
(0.01)
(0.01)
0.0389
(0.28)
Semi Deviation
0.9752
1.93
N/A
1.0
N/A
N/A
N/A
1.23
N/A
2.05
Information Ratio
0.0444
0.064
N/A
0.1054
(0.11)
(0.07)
(0.21)
0.1899
(0.05)
0.0075
Value At Risk
(1.67)
(4.20)
N/A
(2.11)
(6.88)
N/A
(4.12)
(1.97)
(4.15)
(5.27)
Expected Short fall
(3.21)
(1.79)
N/A
(2.21)
N/A
N/A
N/A
(1.48)
N/A
(4.79)
Downside Deviation
2.6
2.27
N/A
1.95
N/A
N/A
N/A
1.6
N/A
6.32
Semi Variance
0.951
3.72
N/A
1.0
N/A
N/A
N/A
1.5
N/A
4.21

Takeda Pharmaceutical Competition Performance Charts

Five steps to successful analysis of Takeda Pharmaceutical Competition

Takeda Pharmaceutical's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Takeda Pharmaceutical in relation to its competition. Takeda Pharmaceutical's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Takeda Pharmaceutical in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Takeda Pharmaceutical's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Takeda Pharmaceutical, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Takeda Pharmaceutical position

In addition to having Takeda Pharmaceutical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Money Funds Thematic Idea Now

Money Funds
Money Funds Theme
Funds or Etfs that invest most if their asset in companies from financial sector such as commercial banks, insurance companies, investment funds, and real estate. The Money Funds theme has 36 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Money Funds Theme or any other thematic opportunities.
View All  Next Launch

Additional Information and Resources on Investing in Takeda Pink Sheet

When determining whether Takeda Pharmaceutical is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Takeda Pink Sheet is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Takeda Pharmaceutical Co Stock. Highlighted below are key reports to facilitate an investment decision about Takeda Pharmaceutical Co Stock:
How To Invest In Takeda
Details
Is Takeda Pink Sheet a good investment?
Details
What is Takeda Pharmaceutical's Net Worth?
Details
Largest Pharmaceuticals Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out Takeda Pharmaceutical Correlation with its peers.
You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Altman
Z Score
Details
Intrinsic
Valuation
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between Takeda Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Takeda Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Takeda Pharmaceutical's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY